TFX earnings / call / takeaways

TFX earnings call: key takeaways

What TFX said on its earnings call of November 5, 2026: results against expectations, what changed since last quarter, guidance and the questions analysts pressed on.

By Lician·November 5, 2026·AI-generated from the call transcript and Lician data

Teleflex reported third-quarter 2026 adjusted EPS of $2.63, which beat the $1.92 consensus estimate (14:00)
The company raised full-year adjusted EPS guidance to $7.50 to $7.75 from $6.90 to $7.20. (14:00)

Results vs expectations

Metric	Consensus	Reported	Result
EPS	$1.92	–	–
Revenue	$565.4M	–	–

What changed since last quarter

Full-year adjusted EPS guidance raised to $7.50-$7.75 from $6.90-$7.20. (23:05)
Interventional business is expected to return to market growth in 2027 with continuous improvement. (31:34)
CEO emphasized the importance of completing the acute care and interventional urology divestiture by year-end. (6:18)

Guidance

Metric	This call	Previous call
Revenue	Full-year revenue growth of 3.5% to 4.5% (23:05)	not captured
Margin	Adjusted operating margin of 20% for 2026 (24:36)	not captured

What analysts pressed on

Whether tariffs will pressure gross margin next year. (38:34)
Concerns about the timeline for the acute care and interventional urology divestiture and its impact on 2027 EPS. (32:29)
Questions about the supply constraints for EasyPlaz and its revenue contribution in 2027. (35:48)

In their words

We have a clear path forward built on three priorities. Jason Weidman (26:57)
EasyPlaz is the first and only FDA-licensed freeze-dried plasma. Jason Weidman (10:58)
We are building a more focused, agile, and growth-oriented Teleflex. Jason Weidman (26:57)

Read the full transcript with the AI summary, or listen on the company's official webcast.

Every past call in full and transcript search come with Lician Pro.

Written by AI from the automatic transcript of the company's public webcast and Lician's earnings data. Each sentence cites the passage it comes from, and a sentence with a figure that is not in its sources was removed. Not investment advice.